Efficacy News and Research

RSS
FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

arGEN-X reports that Phase Ib cancer study with ARGX-110 antibody meets translational development goals

arGEN-X reports that Phase Ib cancer study with ARGX-110 antibody meets translational development goals

Scientists establish a goal of creating vaccine gene chip to speed up vaccine testing

Scientists establish a goal of creating vaccine gene chip to speed up vaccine testing

Scientists continue work to end chemotherapy pain

Scientists continue work to end chemotherapy pain

Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC

Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

OncoSec Medical reports positive interim data from OMS-I100 Phase 2 trial for metastatic melanoma

OncoSec Medical reports positive interim data from OMS-I100 Phase 2 trial for metastatic melanoma

Data show that HCV genotype-1 infected patients may benefit from faldaprevir

Data show that HCV genotype-1 infected patients may benefit from faldaprevir

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

NIH Stroke Trials Network includes UC San Diego Health System as grant recipient

NIH Stroke Trials Network includes UC San Diego Health System as grant recipient

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

IOF Young Investigator Awards presented to five researchers at 4th Asia-Pacific Osteoporosis Meeting

IOF Young Investigator Awards presented to five researchers at 4th Asia-Pacific Osteoporosis Meeting

NIH names UTHealth as one of 25 regional stroke centers

NIH names UTHealth as one of 25 regional stroke centers

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Cetuximab fails in second-line combination for recurrent NSCLC

Cetuximab fails in second-line combination for recurrent NSCLC

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.